| 1 |
Librexia AF is a randomized study to evaluate the efficacy and safety of mlivexian versus apixaban in atrial fibrillation. |
National Leader: Dr Denis Xavier |
Type 1 |
2024 |
Ongoing |
| 2 |
SJRI - Librexia AF is a randomized study to evaluate the efficacy and safety of mlivexian versus apixaban in atrial fibrillation. |
National Leader: Dr Denis Xavier |
Type 1 |
2024 |
Completed |
| 3 |
Librexia AF is a randomized study to evaluate the efficacy and safety of mlivexian versus apixaban in atrial fibrillation. |
National Leader: Dr Denis Xavier |
Type 1 |
2024 |
Completed |
| 4 |
Breast Cancer Screening Program |
Dr Charles King |
Type 2 |
2023 |
Completed |
| 5 |
Novel Vaccine Development |
Dr Marcus Wong |
Type 1 |
2023 |
Completed |
| 6 |
Study on Cardiovascular Health |
Dr Jardin Lee |
Type 1 |
2023 |
Completed |
| 7 |
Long-term Diabetes Care Study |
Dr Mary Hill |
Type 2 |
2022 |
Completed |
| 8 |
Stroke Rehabilitation Trial |
Dr Josephine Liew |
Type 2 |
2022 |
Completed |
| 9 |
Metabolic Disorders Clinical Trial |
Dr Susan Ray |
Type 2 |
2022 |
Completed |
| 10 |
AI in Drug Discovery |
Dr Bruce Klein |
Type 1 |
2021 |
Ongoing |
| 11 |
COVID-19 Response Strategies |
Dr Blanca Perez |
Type 1 |
2021 |
Completed |
| 12 |
Cancer Immunotherapy Progress |
Dr Anna Li |
Type 1 |
2021 |
Completed |
| 13 |
Neurocognitive Aging |
Dr Nihal Patel |
Type 1 |
2020 |
Completed |
